SCHEMBL18740351

SCHEMBL18740351

COC(=O)c1c(C(F)(F)F)nn2c1N(c1ccc(C(F)(F)F)cc1)CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOX4 Q9NPH5 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ CISD2 Q8N5K1 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CFTR P13569 1/20 0.36
▸ FPR2 P25090 5/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ CCR1 P32246 1/20 0.35
▸ FPR1 P21462 3/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ GRIA2 P42262 1/20 0.35
▸ TLR2 O60603 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18740013 0.93 CISD2 (0.39) NOX4LMNAPKMCISD2MEN1
SCHEMBL18739970 0.86 NOX4 (0.37) NOX4MEN1KMT2AFPR2ALDH1A1
SCHEMBL18758538 0.83 PDE2A (0.43) ALDH1A1CYP2C9
SCHEMBL18758616 0.83 BRD4 (0.42) LMNAALDH1A1POLBGAAMAPT
SCHEMBL18740168 0.82 KDM4E (0.41) LMNAPKMMEN1KMT2AKDM4E
SCHEMBL18740275 0.81 LMNA (0.46) LMNAMEN1KMT2AALDH1A1POLB
SCHEMBL18740127 0.79 NOTUM (0.39) MEN1KMT2AFPR2MAPTCCR1
SCHEMBL18758566 0.77 PTGER4 (0.42) ALDH1A1CYP2C9
SCHEMBL18740120 0.77 PTGER4 (0.49) CYP2C9
SCHEMBL18740123 0.77 PTGER4 (0.49) CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434246-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2022-09-06 — — US disclosed
EP-3362454-B1 EP4 ANTAGONISTS EISAI R&D MAN CO LTD (JP) 2021-12-08 — — EP disclosed
EP-3362454-B1 EP4 ANTAGONISTS EISAI R&D MAN CO LTD (JP) 2021-12-08 — — EP disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
US-20180305362-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-10-25 — — US disclosed
EP-3362454-A1 EP4 ANTAGONISTS Eisai R&D Management Co., Ltd. (JP) 2018-08-22 — — EP disclosed
WO-2017066633-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-20 — — WO disclosed
WO-2017066633-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434246-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 NOX4 3356/4885LMNA 3809/4885PKM 1460/4885
US-20180305362-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 NOX4 3356/4885LMNA 3809/4885PKM 1460/4885
US-10316040-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 NOX4 3356/4885LMNA 3809/4885PKM 1460/4885
US-10941148-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 NOX4 3356/4885LMNA 3809/4885PKM 1460/4885
US-20190315754-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 NOX4 3356/4885LMNA 3809/4885PKM 1460/4885
US-20210347779-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 NOX4 3356/4885LMNA 3809/4885PKM 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback